| Biomarker ID | 362 |
| PMID | 18593988 |
| Year | 2008 |
| Biomarker | IL8 + Osteopontin |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Recurrent Group |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(CXCL8):-Cytokines and inflammatory response,FRA pathway, PERK-regulated gene expression,Interleukin-7 interactions in immune response,Corticotropin releasing hormone pathway |
| Experiment | Reccurance Free Survival Vs Recurrance in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 103 prostatectomy specimens were obtained with a 72 month follow up period. 53 cases of Biochemical reccurrances and 50 patients with no recurrance. |
| Senstivity | 95% (Monte Carlo Cross Validation 86 ± 8.5%) |
| Specificity | 65% (Monte Carlo Cross Validation 60.5 ± 6.5%) |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CXCL8, SPP1 |